Evidence map›Paper›PMID 41629324›Full record

ReviewNPJ vaccines2026

The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine.

Ian Escudero, Dieter Gniel, Shibadas Biswal, Eckhardt Petri, Gonzalo Perez, Mayuri Sharma, John Weil, Derek Wallace

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Dengue outbreaks in China during 2005-2023: a systematic analysis.Frontiers in cellular and infection microbiology · 2026
    Pooled it
  2. Article
  3. Dengue NS1 as a Driver of Immune-Mediated Pathogenesis.Tropical medicine and infectious disease · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Ian EscuderoTakeda Vaccines, Inc., Boston, MA, USA. ian.escudero@takeda.com.
Dieter GnielTakeda Pharmaceuticals International AG, Zurich, Switzerland.
Shibadas BiswalTakeda Vaccines, Inc., Boston, MA, USA.
Eckhardt PetriTakeda Pharmaceuticals International AG, Zurich, Switzerland.
Gonzalo PerezTakeda Vaccines, Inc., Boston, MA, USA.
Mayuri SharmaTakeda Vaccines, Inc., Boston, MA, USA.
John WeilTakeda Pharmaceuticals International AG, Zurich, Switzerland.
Derek WallaceTakeda Vaccines, Inc., Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The approved, live-attenuated tetravalent dengue vaccine TAK-003 has undergone extensive preclinical and clinical assessment. This review provides an overview of the rationale for some key decisions made during TAK-003 development. These include decisions around vaccine composition, assessment of factors that may be associated with the safety of live-attenuated viral vaccines, dosing schedule, immunogenicity assessments, and design of the pivotal phase 3 efficacy study.

Identifiers

PMID41629324
PMCPMC12894967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.